Abstract Erythropoietin ( EPO) is a 34 kDa protein of chronic renal failure, the anaemia associated with HIV patients treated with AZT, cancer chemotherapy that is the primary regulator of red blood cell production. EPO facilitates its effect by binding to the cell patients and autologous blood predonation. EPO exerts its actions through the membrane-bound EPO surface EPO receptor which initiates the JAK-STAT signal transduction cascade. The search for small receptor present on the cell surface. The EPO receptor is a 484 amino acid glycoprotein member of the mimetic molecules of EPO has led to the discovery of a family of peptides that demonstrate EPO mimetic cytokine receptor superfamily which includes the receptors for growth hormone, IL-3, TPO, G-CSF and activity. A member of this peptide family, EMP1 ( EPO mimetic peptide 1), was used to solve the crystal others [2, 3] . The receptor plays a central role in EPO signal transduction, which is facilitated through the structure of the soluble EPO receptor in complex with this peptide. The structure revealed a 252 stoichiometry JAK-STAT pathway and ultimately results in cellular proliferation and maturation [4] . of receptor to peptide, with each peptide contacting both receptor molecules in a symmetrical fashion. The
Erythropoietin
peptide libraries have been used for a number of ligand-receptor interactions in the hope of identifying Erythropoietin ( EPO) is a 34 kDa hormone that is the a novel agonist/antagonist. Peptides displayed on primary regulator of erythropoiesis in mammals [1] . phage were used first to identify peptides that could EPO is produced primarily in the kidneys and its bind to the extracellular domain of the EPO receptor. biosynthesis is controlled by a feedback mechanism in Libraries centred around this initial lead peptide were response to hypoxia. The recombinant hormone, epo-then generated to produce an agonist peptide [8] . The etin, is specific for erythroid progenitors and shows resulting family of peptides contained the conserved little effect on other cell types. EPO has been used for amino acid residues outlined in Figure 1 . The peptide a number of clinical indications, including the anaemia was named EPO mimetic peptide 1 or EMP1. EMP1 was cyclic by virtue of the two cysteine residues and Correspondence and offprint requests to: Francis P. Barbone, The had conserved amino acids at positions 4, 9, 10,12, 13 the assays for EPO function. N-and C-terminal deletions resulted in a minimal active peptide having the sequence designated EMP20 (Table 1 ). The peptide must be cyclic in order to retain activity, and alanine scanning substitutions revealed that the conserved residues shown in Figure 1 are also critical for peptide Fig. 1 . The amino acid sequence of EMP1. Conserved residues are activity. This is especially true for the tyrosine (Y ) at in bold. The bar joins the two cysteine residues. position 4. A number of amino acid substitutions at position 4 tyrosine were generated, resulting in reduced panel of assays to determine if it was truly an erythro-activity of these peptides [10] . One peptide, designated poietin mimic.
EMP33, contains a 3,5-dibromo-tyrosine at the number EMP1 was shown to compete for binding against 4 position. This peptide binds to cells with an IC 50 of radioactively labelled EPO, to cause proliferation of 15 mM, a lower affinity than EMP1 (0.1 mM ) but within an EPO-responsive cell line and to induce the same the range of IC 50 values for other peptides that maintain intracellular phosphorylation pattern as EPO [8] . in vitro biological activity, i.e. stimulation of cell prolif-EMP1 also causes erythroid colony formation of eration. EMP33 will be discussed in more detail below. human bone marrow and peripheral blood.
The possibility of increasing the activity of EMP1 by Furthermore, EMP1 was shown to be active in two covalent dimerization of the peptide was explored different in vivo models of EPO activity. The first in through two avenues. One method utilizes a difunctional vivo assay utilizes normal untreated animals that polyethylene glycol (PEG) molecule as the means of receive subcutaneous injections of EMP1. In vivo activjoining two peptides through their N-terminus. The ity for EMP1, i.e. stimulation of newly differentiated EMP1 PEG dimer was then purified by HPLC and reticulocytes, was observed for this peptide in a backverified by MALDI-TOF mass spectral analysis, indicatground of endogenous EPO. The second in vivo study ing the appropriate mass of the PEG dimer [11] . The is the exhypoxic polycythaemic mouse bioassay. This assay conditions mice over a period of 14 days under second method utilized a C-terminal lysine residue as hypobaric conditions that render the mice polycy-the main branch point for the attachment of the two thaemic, and effectively shut down EPO production EMP1 peptides. This dimer peptide was referred to as when the mice are brought to ambient pressure. the chemical dimer and was checked for purity and EMP1 demonstrated activity across the dose range accurate mass [12] . The dimer peptides were then (1.0-54.0 mg/mouse) in the stimulation of new red subjected to the same biological assays as described blood cell production [8] .
previously for the monomer peptides. The EMP1 PEG dimer had an improved binding IC 50 on TF-1 cells of 28 nM as compared with 100 nM for the monomeric EMP1-EBP structure peptide and 0.75 nM for the chemical dimer. The ED 50 for cell proliferation improved from 100 nM to 2 nM Crystals suitable for structural analysis were obtained for the PEG dimer and further improved to 1 nM for for the EBP-EMP1 protein complex. The complex the chemical dimer (Table 2 ). This increase in binding reveals a symmetrical structure with a 252 stoichi-and in vitro activity was carried further in the exhypoxic ometry of EMP1 to EBP. Each peptide within the polycythaemic mouse bioassay where EMP1, PEG structure interacts with both receptor subunits, identi-dimer and chemical dimer yielded in vivo equivalents to fying the contact residues between peptide and receptor 0.025 U of EPO of 3.8, 0.28 and 0.035 nmol, respect- [9] . One of the receptor residues is Phe93, which was ively. However, the dimer peptides could not approach mentioned earlier as being a critical binding determin-the in vivo value for EPO of 0.0000058 nmol. This ant for EPO based on mutagenesis studies. Phe93 is indicates that while the in vitro activity of the dimer also important for the interaction of EMP1 with the peptides was markedly improved, the in vivo activity EPO receptor. Therefore, the structural data support remained significantly less than that of EPO (Table 2) . the original functional data of the receptor mutants.
This was also true for the chemical dimer, which had a The structure of EMP1 in complex with EBP demonstrates that a peptide of~2.0 kDa is capable of activating the EPO receptor and mimicking the 34 kDa EPO protein. This minimized hormone can then be Table 1 . EMP20 is the designated sequence for the minimal active used as a stepping stone for the design and discovery peptide that retains activity in the assays for EPO function. of a truly minimal functional mimetic that could be orally available.
Designation Sequence
EMP1 GGTYSCHFGPLTWVCKPQGG

Increased activity of EMP1
EMP20 YSCHFGPLTWVCK EMP33 GGTXSCHFGPLTWVCKPQGG The next step in the characterization of EMP1 was to determine the minimal peptide that retained activity in X=3,5-dibromo-tyrosine. (Figure 3) . The signal is initiated following the binding of EPO and dimerization of the receptor. JAK2 proportional increase in in vivo potency. Taken together, undergoes autophosphorylation and subsequently phosthese data support the hypothesis that there are multiple phorylates the EPO receptor and the STAT proteins, ways of activating the EPO receptor, but clearly the which translocate to the nucleus and activate transcripnatural ligand has an advantage in this regard.
tion. Haematopoietic cell phosphatase (HCP), also known as SHP1 or PTP1C, binds to the phosphorylated EPO receptor and undergoes a conformational change
Non-productive receptor complex
allowing it to dephosphorylate JAK2. HCP therefore acts as a negative regulator of the EPO signalling The substitution of amino acid residues of EMP1 led cascade [15] . HCP provides a viable target for a small to the identification of those amino acids of the cyclic molecule since an inhibitor of HCP could augment EPO peptide that were important for binding and activation action, allowing for lower doses of EPO. of the EPO receptor [10] . These studies included the The rationale for this approach includes the fact substitution of non-natural amino acids within EMP1, that cells expressing a truncated EPO receptor are as described earlier. EMP33 contains a 3,5-dibromo hypersensitive to EPO. The truncated receptor lacks tyrosine at position 4 of the cyclic peptide. This peptide the C-terminal region that is the binding site for HCP. has been shown to bind to the EPO receptor but is HCP is unable to dephosphorylate JAK2 and, as a inactive in the cell proliferation assay. EMP33 does result, the negative effect of HCP is eliminated. In not cause the proliferation of EPO-responsive cells, addition, antisense oligonucleotides directed to HCP nor the intracellular phosphorylation of proteins char-enhance haemoglobinization in SKT6 cells [16 ] . acteristic of the EPO signalling response. EMP33 was Clinical data exist demonstrating that a truncated used to generate crystals in complex with the EBP, human EPO receptor causes benign erythrocytosis due and the structure of the EMP33-EBP complex has to loss of the interaction of HCP with the cytoplasmic been solved [13] . This structure is similar to the domain of the EPO receptor [17] . The increased sensit-EMP1-EBP active complex with a 252 stoichiometry ivity to EPO, as a result of reduced activity of HCP, of receptor subunits to peptides. However, when super-suggests that HCP is a target worth pursuing in the imposed onto the active EMP1-EBP complex, the search for an EPO enhancer. inactive EMP33-EBP complex shows a 15°rotation
The gene for HCP has been cloned and the protein that apparently is sufficient to cause this complex to expressed in E. coli. The enzyme has been used in a be inactive. The slight perturbation of the dimeric screening assay to identify potential inhibitors from a complex suggests that simple dimerization of receptor library of compounds. Inhibitors were identified from subunits is not the only requirement for activation of the library, and IC 50 values were determined for a the EPO receptor. This had been the general thinking number of these compounds. An example of compounds that inhibit HCP is shown in Figure 4 . These due to the ability of antibodies to activate receptors compounds inhibit HCP in the 10-30 mM range. through dimerization [14] . Clearly, the configuration Compounds are then tested in the cell proliferation of the receptor-ligand complex has an impact on the assay using a suboptimal dose of EPO. Inhibition of activation of the receptor. This may be related to the HCP by the compound results in a dose-dependent lower potency of the peptide analogues of EMP1 that increase in cell proliferation (data not shown). have shown increased receptor binding activity but Additional secondary assays include the extended remain less biologically active than the natural ligand.
phosphorylation state of JAK2 and STAT5 in the The active and inactive receptor-peptide complexes presence of an HCP inhibitor. HCP inhibitors that are can be used to help guide the design of small molecules shown to augment EPO action will be tested further that potentially could be EPO mimetics ( Figure 2) .
in red blood cell colony assays and in the mouse reticulocyte assay [18] .
Haematopoietic cell phosphatase (HCP, SHP1) Future directions
Another approach to identifying orally available small molecule mimetics of EPO is to target the intracellular The discovery of new erythropoietic molecules is a difficult challenge especially when faced with the excelsignal transduction cascade of the EPO receptor lent profile of the natural ligand, EPO. EMP1 is an example of a peptide that has no sequence homology to EPO but is capable of activating the EPO receptor. These data keep the doors of opportunity open such that a small molecule mimetic may be possible. These peptides can be used in conjunction with the EMP-EBP structures for the rational design of potential mimetic molecules. The solved structure of the EMP1-EBP active complex, as well as the EMP33-EBP inactive complex, provide insight into the requirements for receptor activation and the subtle changes that can produce a non-productive receptor dimer. The continued examination of these molecules and complex structures will hopefully lead to a potent small molecule EPO mimetic.
Additionally, targets such as HCP can be exploited with the potential to supplement epoetin therapy or perhaps replace it completely. The intracellular proteins that conduct the signals may be useful points at which to intervene. These approaches are critical for the discovery of new molecules that possess the potency and activity of EPO.
